Guatemala. Centroamérica enfrenta desafíos importantes en cuanto a la seguridad alimentaria y Guatemala, no es la excepción, esto afecta principalmente a las poblaciones más vulnerables, incluidos niñ ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

This year, pharmaceutical giant Merck (NYSE: MRK) is it: The drugmaker's shares are down by 2% in 2024 while the broader S&P 500 is up by 21%. Even when we zoom out, Merck hasn't performed ...

Alpha-9 Oncology has raised $175m in a Series C funding round to advance its pipeline of radiopharmaceuticals. Credit: eamesBot via Shutterstock. Alpha-9 Oncology is the latest radiopharma to raise ...

NEW YORK (AP) — U.S. health officials on Wednesday recommended that people 50 and older get a shot against bacteria that can cause pneumonia and other dangerous illnesses. The recommendation was ...

Image credit: Sergiy Palamarchuk / Shutterstock. MSD (Merck & Co) is planning to get its respiratory syncytial virus (RSV) vaccine, clesrovimab, approved and launched before the next RSV season in ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Merck KGaA's shares jumped after the German company said booming artificial-intelligence demand would help its electronics sales grow faster than previously expected over the medium term. The life ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

The results suggest that CAPVAXIVE could offer broader protection against pneumococcal disease. Merck Scientific Advisory Committee member Dr Walter Orenstein said: “Adults with chronic medical ...

German pharma and technology giant Merck has announced a €5 million (£4.2m) investment in Scotland that will create further jobs at its diagnostics and blood typing facility in Livingston.

Merck Research Laboratories global clinical development oncology senior vice-president and head Dr Marjorie Green said: “We look forward to working with our colleagues at Exelixis to advance these ...